The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP CRN 2025 RFA Scientific Track, 2026Seeded Aggregation of Alpha-Synuclein
Study Rationale:
Filamentous aggregates of the protein alpha-synuclein underlie several neurodegenerative diseases, called synucleinopathies. Parkinson’s disease (PD) is the most common...
-
ASAP CRN 2025 RFA Scientific Track, 2026Aging and the Heterogeneity of Parkison’s Disease – The Role of Heterochromatin Erosion
Study Rationale:
Age is the single most significant risk factor for developing Parkinson’s disease (PD), but the mechanisms by which aging contributes to PD are not well...
-
ASAP CRN 2025 RFA Scientific Track, 2026CLEAR-PD: Clearance via Lymphatics & Endocytic Alpha-Synuclein Receptors in Parkinson’s Disease
Study Rationale:
In Parkinson’s disease (PD), it is clear that the alpha-synuclein protein accumulates in specific neurons, thereby damaging them to cause neurological symptoms...
-
ASAP CRN 2025 RFA Scientific Track, 2026Decoding Co-Pathological Mechanisms in Parkinson's Disease: From Molecular Interactions to Disease Progression
Study Rationale:
Parkinson's disease involves multiple abnormal proteins—α-synuclein, tau, and TDP-43—that clump together in brain cells. These protein clumps don't act alone; they work...
-
ASAP CRN 2025 RFA Scientific Track, 2026Mitochondrial Surface as a Neuroprotective Signal Integrator in PD
Study Rationale:
Accumulation of damage to the cellular batteries (mitochondria) in the brain is a major driver of PD. Analysis of two genes PINK1 and PARKIN have provided...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.